Moore Capital Management’s Ibere Pharmaceuticals IBER Stock Holding History

Moore Capital Management’s Portfolio IBER Stock Details IBER Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-300,000	Closed	-$3.03M	–	630
2022 Q4	$3.03M	Hold	300,000	–	–	0.07%	216
2022 Q3	$2.97M	Hold	300,000	–	–	0.07%	289
2022 Q2	$2.94M	Hold	300,000	–	–	0.08%	271
2022 Q1	$2.94M	Hold	300,000	–	–	0.07%	300
2021 Q4	$2.92M	Hold	300,000	–	–	0.06%	325
2021 Q3	$2.91M	Hold	300,000	–	–	0.04%	378
2021 Q2	$2.9M	Buy	+300,000	New	+$2.92M	0.04%	388

Moore Capital Management's IBER Position: Q1 2023 in Review

Moore Capital Management sold out of Ibere Pharmaceuticals (IBER) in Q1 2023, closing a stake of 300,000 shares — an estimated $3.03M sold.

Moore Capital Management first reported a position in IBER in Q2 2021 and held it in 7 quarters. The position peaked at $3.03M in Q4 2022. 0 funds tracked by Wall St. Rank hold IBER as of Q1 2023.

Moore Capital Management reported no remaining Ibere Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Moore Capital Management sold 300,000 Ibere Pharmaceuticals shares in Q1 2023, an estimated $3.03M.
Moore Capital Management first reported a position in Ibere Pharmaceuticals in Q2 2021 and held it in 7 quarters.
Moore Capital Management's Ibere Pharmaceuticals position peaked at $3.03M in Q4 2022.
0 funds tracked by Wall St. Rank held Ibere Pharmaceuticals as of Q1 2023.

Based on Moore Capital Management's 13F filing for Q1 2023, filed 15 May 2023.